Brigatinib package insert: Key information and precautions for use

Brigatinib (Brigatinib) is a targeted drug used to treat non-small cell lung cancer (NSCLC) EGFR mutations. It is a tyrosine kinase inhibitor (TKI). According to the package insert for brigatinib, the following is some key information and special precautions when using it.

1. Indications and efficacy:

Brigatinib is mainly used to treat patients who have received afatinib (Afatinib) or erdatinib (Erlotinib) and other EGFR inhibitors treatment for patients with advanced or metastatic EGFR mutation-positive non-small cell lung cancer. It prevents the growth and spread of tumor cells by inhibiting the activity of EGFR mutations. Brigatinib has better clinical effects on some advanced patients, especially those who have become resistant to first-line treatment. Its efficacy and resistance management are particularly important.

2. Usage and dosage:

The standard dose of brigatinib is taken orally once daily, with the initial dose usually being 90 mg. If the patient is able to tolerate the drug, the dose can be gradually increased to 180mg based on treatment response. This dose adjustment usually occurs on the 7th day of treatment and is done under the guidance of a physician. Tablets should be swallowed whole and not crushed or chewed. In addition, brigatinib can be taken with food, but excessive alcohol consumption needs to be avoided as alcohol may increase the side effects of brigatinib.

3. Adverse reactions and management:

Side effects of brigatinib include, but are not limited to, pneumonia, cough, dyspnea, hyperglycemia, abnormal liver function, headache, rash, musculoskeletal pain, etc. During the treatment process, patients should pay close attention to their discomfort and report it to the doctor in time. Especially in the early stages of drug use, patients may experience severe pulmonary reactions or allergic reactions, and doctors may adjust the dosage or temporarily discontinue the drug based on the specific situation. In addition, patients should undergo regular blood routine and liver and kidney function tests to monitor the effects of the drug on the body.

4. Special groups and contraindications:

Brigatinib should be used with caution in certain populations. For example, for women who are pregnant or breastfeeding, brigatinib falls under the FDA pregnancy categoryD, may cause harm to the fetus, it is recommended to avoid use. The use of brigatinib also requires special caution in patients with impaired hepatic function, often requiring dose adjustment. Use is contraindicated in patients who are allergic to brigatinib or its components. In addition, brigatinib may interact when used in combination with other drugs, especially when combined with certain drugs (such as CYP3A inhibitors), which may require adjustment of the brigatinib dose or interval.

5. Monitoring and precautions:

During the treatment process, doctors need to regularly monitor the patient's lung function, liver and kidney function, etc., in order to detect early symptoms of side effects in a timely manner. Especially for lung problems, if symptoms such as coughing and difficulty breathing occur, the doctor should be informed immediately so that relevant examinations can be carried out and the treatment plan can be adjusted. If patients experience allergic reactions, severe diarrhea, or skin reactions, the drug may need to be stopped and managed accordingly. In patients with diabetes, brigatinib may cause an increase in blood sugar, so blood sugar levels should be monitored closely.

In short, brigatinib is an effective targeted drug that can help patients with non-small cell lung cancer prolong survival and improve quality of life. However, when using it, special attention must be paid to side effects, liver and kidney function, blood sugar and other aspects of monitoring to ensure the safety and effectiveness of the treatment. During the medication process, patients should strictly follow the doctor's instructions and undergo regular check-ups to obtain the best effect.

Reference materials:https://www.alunbrig.com/